Insulin glargine,300 U/mL; Insulin glargine (100 units /mL); Background therapy
Проводит Sanofi
Страница компании6-Month, Multicenter, Randomized, Open-label, 2-Arm, Parallel-group Study Comparing the Efficacy and Safety of a New Formulation of Insulin Glargine and Lantus® Injected Once Daily in Children and Adolescents Age 6 - 17 Years With Type 1 Diabetes Mellitus With a 6-month Safety Extension Period
Постоянная ссылка: https://clinomir.ru/trials/nct/NCT02735044/
Источник: ClinicalTrials.gov (U.S. National Library of Medicine). Что откуда
Простыми словами
Словарь терминов- Фаза III — большое исследование: новый препарат сравнивают со стандартным лечением или плацебо, чтобы доказать пользу и безопасность.
- Исследование завершено, новых участников не набирают.
- Возраст участников: 6–17 лет. Остальные условия — в блоке «Кто может участвовать».
- По плану участвуют 463 чел. во всех странах исследования.
- Плановая дата окончания (12.2018) уже прошла.
Пересказ собран автоматически из данных реестра, без оценки пользы и рисков. Подробно о рисках и пользе рассказывает врач центра перед подписанием согласия.
Кто может участвовать
Полный текст критериев (на английском, как в ClinicalTrials.gov) · включение: 2 · невключение: 13
Критерии включения
- Children and adolescents with type 1 diabetes mellitus (T1DM) for at least 1 year confirmed by typical symptoms at diagnosis and/or by antibody testing \[presence of anti-GAD (glutamic acid decarboxylase) or anti-IA2 (islet antigen 2/tyrosine phosphatase) or anti-islet cell antibodies\] and/or clinical features (eg, history of ketoacidosis)\].
- Signed written informed consent obtained from parent(s)/legal guardian and written or oral assent obtained from participant.
Критерии невключения
- Age <6 years and >=18 years at randomization.
- Less than 1 year on insulin treatment prior to screening visit.
- Less than 6 months on basal plus mealtime insulin and self-monitoring of blood glucose prior to screening visit.
- Participants using premix insulins in the last 3 months before screening visit or participants using human regular insulin as mealtime insulin in the last 3 months before screening visit.
- Use of an insulin pump in the last 6 months before screening visit or plans to switch to pump within the next 6 months after screening visit.
- Any contraindication to use of insulin glargine as defined in the national product label.
- No willingness to inject insulin glargine (Lantus or HOE901-U300) once daily.
- HbA1c <7.5% or >11% at screening.
- Initiation of any glucose-lowering medications in the last 3 months before screening visit.
- Hospitalization or care in the emergency ward for diabetic ketoacidosis or history of severe hypoglycemia (as defined by need for glucagon or IV glucose) and accompanied by seizure and/or unconsciousness and/or coma in the last 3 months prior to screening visit.
- Postmenarchal girls not protected by highly-effective method(s) of birth control and/or who were unwilling or unable to be tested for pregnancy. Abstinence from sexual intercourse was considered as an acceptable form of birth control.
- Pregnant or breast-feeding adolescents, or adolescents who intended to become pregnant during the study period, or who were at risk of getting pregnant due to any psychosocial reason during the study period.
- The above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.
Источник: ClinicalTrials.gov, NCT02735044 · запись обновлена в реестре 25 марта 2022.
Дизайн и результаты
Что измеряют — первичные конечные точки (1), вторичных — 10
- Change From Baseline in HbA1c to Month 6 — Baseline to Month 6
Цель исследования
Primary Objective:
To compare the efficacy of a new formulation of insulin glargine (HOE901-U300) to Lantus in terms of change of HbA1c from baseline to endpoint (month 6) in children and adolescents with type 1 diabetes mellitus.
.
Secondary Objectives:
To compare HOE901-U300 and Lantus in terms of:
* Percentage of participants reaching target HbA1c and fasting plasma glucose (FPG).
* To assess the safety of HOE901-U300 including analysis of events of hypoglycemia, events of hyperglycemia with ketosis, and development of anti-insulin-antibodies.
Где проходит
0 центровЦентры в реестре не указаны.
Откуда эта информация
-
ClinicalTrials.gov (U.S. National Library of Medicine) · NCT02735044 Официальный реестр (США) · загружено 9 ноября 2026Препарат, номер протокола, название, цель, фаза, статус, сроки, число участников, спонсор
Сведения сведены и нормализованы порталом «Клиномир»: названия компаний и центров приведены к одному написанию. Нашли ошибку? Напишите нам — исправим.